Literature DB >> 17547837

Prevention of type 2 diabetes: an update.

Amal Farag1, Jocelyne Karam, John Nicasio, Samy I McFarlane.   

Abstract

With the rising tide of the diabetes epidemic leading to increased morbidity and mortality (primarily from cardiovascular disease), together with failure to control the disease and its associated complications, prevention of diabetes appears to be the logical option for curbing this epidemic. Several trials have been completed, and others ongoing, using various strategies for diabetes prevention. In this review, we provide an update on diabetes prevention strategies, highlighting the rationale behind such interventions, together with an outlook of the ongoing efforts that are likely to provide additional options for patients at risk for diabetes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17547837     DOI: 10.1007/s11892-007-0032-4

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  51 in total

1.  Effects of slow release bezafibrate on the lipid pattern and on blood glucose of type 2 diabetic patients with hyperlipidaemia.

Authors:  A Rovellini; D Sommariva; A Branchi; F Maraffi; C Montalto; R Gandini; A Fasoli
Journal:  Pharmacol Res       Date:  1992-04       Impact factor: 7.658

Review 2.  Diabetes, hypertension, and cardiovascular disease: an update.

Authors:  J R Sowers; M Epstein; E D Frohlich
Journal:  Hypertension       Date:  2001-04       Impact factor: 10.190

3.  Preventing type 2 diabetes using combination therapy: design and methods of the CAnadian Normoglycaemia Outcomes Evaluation (CANOE) trial.

Authors:  B Zinman; S B Harris; H C Gerstein; T K Young; J M Raboud; J Neuman; A J G Hanley
Journal:  Diabetes Obes Metab       Date:  2006-09       Impact factor: 6.577

4.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

Authors:  Luc F Van Gaal; Aila M Rissanen; André J Scheen; Olivier Ziegler; Stephan Rössner
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

5.  Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study.

Authors:  X R Pan; G W Li; Y H Hu; J X Wang; W Y Yang; Z X An; Z X Hu; J Lin; J Z Xiao; H B Cao; P A Liu; X G Jiang; Y Y Jiang; J P Wang; H Zheng; H Zhang; P H Bennett; B V Howard
Journal:  Diabetes Care       Date:  1997-04       Impact factor: 19.112

6.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

7.  Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.

Authors:  André J Scheen; Nick Finer; Priscilla Hollander; Michael D Jensen; Luc F Van Gaal
Journal:  Lancet       Date:  2006-11-11       Impact factor: 79.321

Review 8.  Effects of exercise on insulin sensitivity in humans.

Authors:  J T Devlin
Journal:  Diabetes Care       Date:  1992-11       Impact factor: 19.112

9.  Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.

Authors:  Alexander Tenenbaum; Michael Motro; Enrique Z Fisman; Ehud Schwammenthal; Yehuda Adler; Ilan Goldenberg; Jonathan Leor; Valentina Boyko; Lori Mandelzweig; Solomon Behar
Journal:  Circulation       Date:  2004-05-03       Impact factor: 29.690

10.  Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study.

Authors:  S D Long; K O'Brien; K G MacDonald; N Leggett-Frazier; M S Swanson; W J Pories; J F Caro
Journal:  Diabetes Care       Date:  1994-05       Impact factor: 19.112

View more
  6 in total

1.  Inhibition of the RAS and prevention of diabetes and CVD: mechanistic insights and lessons learned from clinical trials.

Authors:  Samy I McFarlane; Jeffrey S Borer
Journal:  Curr Diab Rep       Date:  2009-02       Impact factor: 4.810

Review 2.  Prevention and current onset delay approaches of type 2 diabetes mellitus (T2DM).

Authors:  Selma B Souto; Eliana B Souto; Daniel C Braga; José L Medina
Journal:  Eur J Clin Pharmacol       Date:  2011-04-06       Impact factor: 2.953

Review 3.  Update on the prevention of type 2 diabetes.

Authors:  Jocelyne G Karam; Samy I McFarlane
Journal:  Curr Diab Rep       Date:  2011-02       Impact factor: 4.810

4.  Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: prevalence of and risk factors for diabetes mellitus in CKD in the Kidney Early Evaluation Program (KEEP).

Authors:  Samy I McFarlane; Peter A McCullough; James R Sowers; Kyaw Soe; Shu-Cheng Chen; Suying Li; Joseph A Vassalotti; Lesley A Stevens; Moro O Salifu; Manjula Kurella Tamura; Andrew S Bomback; Keith C Norris; Allan J Collins; George L Bakris; Adam T Whaley-Connell
Journal:  Am J Kidney Dis       Date:  2011-03       Impact factor: 8.860

Review 5.  Antidiabetic medications and weight gain: implications for the practicing physician.

Authors:  Samy I McFarlane
Journal:  Curr Diab Rep       Date:  2009-06       Impact factor: 4.810

6.  Effects of Lifestyle Modifications and Dietary Habits on Prevention of Diabetes and Cardiovascular Disease.

Authors:  Samy I McFarlane; Azizi A Seixas; Charles Agyemang; Girardin Jean-Louis
Journal:  J Diabetes Res       Date:  2018-12-11       Impact factor: 4.011

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.